This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Confirming post #90 from a second method, which matters more than confirming it from a second person.
Where a manufacturer runs a direct supply route, that is a commercial arrangement rather than a regulatory change, and it can end.
If anyone can point at the primary source I would be grateful.
Telehealth prescribing: widespread in the US and varying in quality. Models without a clinician reviewing measurements and history are not recommended by this community.
None of the above is medical advice and I am not qualified to give any.
Post #92 describes the usual case. This is about the unusual one.
Telehealth prescribing models would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Post #94 is the version of this I will quote in future. One addition.
Telehealth prescribing models is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Where I part company with post #92, and it is a narrow parting.
Anyone reporting an outcome should give the stated reason rather than the verdict. The reason is the part somebody else can use.
The claim is narrower than it sounds, and deliberately so.
An update on my earlier telehealth prescribing models post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Small methodological point on telehealth prescribing models: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
I read post #96 twice before replying, because I had assumed the opposite.
Cost comparisons should state whether they include the device and the dispensing fee, because those differ between routes and between states.
I have written this out at length because the short version keeps being misread.
Post #100 is right about the mechanism and I think understates the practical bit.
Offering a way to settle telehealth prescribing models rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the North America category
US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…
|
+3 | 7 | 43k | 9mo |
|
US compounding rules and how they changed
US compounding rules and how they changed — setting out what I have, and where I think it stops being reliable. Reporting a regional experience with the date and the jurisdiction attached, because an undated…
|
+62 | 68 | 1.4k | 20mo |
|
Canadian access and provincial variation
Posting this under the heading it deserves: Canadian access and provincial variation Everything below is what sits behind that. Trying to establish the boundary conditions on canadian access and provincial…
|
+74 | 80 | 7.7k | 18mo |
|
Revisiting: US compounding rules and how they changed
On the subject in the title: Revisiting: US compounding rules and how they changed Working notes rather than a conclusion. Regional question, dated February 2026, because everything in this category expires.…
|
+5 | 9 | 26k | 23mo |
|
Coverage in the US: a map of the usual obstacles
Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…
|
+46 | 50 | 7.9k | 5mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
|
+50 | 56 | 780 | 8mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. Working notes on List price versus negotiated price rather than a…
|
+24 | 28 | 50k | 12mo |
|
How shortages have affected compounding permissions
How shortages have affected compounding permissions I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what people here actually do about shortages,…
|
+61 | 71 | 3.6k | 2d |
|
Appeal templates and why they are deliberately unemotional
Posting this under the heading it deserves: Appeal templates and why they are deliberately unemotional Everything below is what sits behind that. A narrow question about appeal templates, deliberately narrow,…
|
+25 | 29 | 764 | 7mo |
|
Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest I have a specific reason for asking rather than idle curiosity, and the context is below. Cheapest option: setting out the arithmetic in full, because I have…
|
+19 | 23 | 1.2k | 12h |